Separately, LADENBURG THALM/SH SH raised Ayala Pharmaceuticals from a neutral rating to a buy rating in a research note on Tuesday, May 30th.
Ayala Pharmaceuticals Stock Performance
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers.
- Five stocks we like better than Ayala Pharmaceuticals
- What is the Hang Seng index?
- Is Enbridge Stock Too Cheap to Pass Up Now?
- How Can Investors Benefit From After-Hours Trading
- 5 Best REIT Alternatives for Passive Real Estate Income
- Pros And Cons Of Monthly Dividend Stocks
- 5 Reasons Kroger Should Be On Every Income Investor Watchlist
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.